<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296790</url>
  </required_header>
  <id_info>
    <org_study_id>PM_L_0167</org_study_id>
    <nct_id>NCT00296790</nct_id>
  </id_info>
  <brief_title>Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      A comparison of Zolpidem Tartrate Extended-Release (Ambien CR)vs. Placebo in the Treatment of
      Insomnia Associated with Generalized Anxiety Disorder (GAD) when Used Concomitantly with
      Escitalopram (Lexapro - antidepressant).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date>February 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate safety and hypnotic efficacy of zolpidem tartrate extended release vs. placebo in treatment of insomnia associated with Generalized Anxiety Disorder when used concomitantly with escitalopram</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To show that treating insomnia from beginning of SSRI (Selective Serotonin Reuptake Inhibitor) treatment for anxiety results in improvement in quality of life and possibly greater response to anti-anxiety therapy</measure>
  </secondary_outcome>
  <enrollment>372</enrollment>
  <condition>Insomnia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolpidem tartrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Male or female between the ages of 21and 64 years, inclusive;

          2. Women must use a medically acceptable form of contraception during the entire study
             period, or: be surgically sterilized, post-menopausal, agree to use double-barrier
             contraception throughout the study period, or must have a negative urine pregnancy
             test prior to randomization;

          3. Must meet the diagnostic requirements of Generalized Anxiety Disorder as defined by
             the Diagnostic and Statistical Manual of Mental Disorders;

          4. Score at least 18 on the Hamilton Rating Scale for Anxiety (HAM-A)

          5. Must be either newly diagnosed or show symptoms of relapse during a period of no drug
             therapy for anxiety.

          6. Subject must experience sleep disturbances at least three nights per week, for at
             least one month prior to study entry, based on historical data.

          7. Subject must be stabilized on all long-term medication therapy for at least one month
             prior to study entry.

        EXCLUSION

          1. History of Post-Traumatic Stress Disorder;

          2. Concomitant Major Depressive Disorder or Bipolar Disorder;

          3. Any abnormal pre-study laboratory values that require clinical intervention

          4. Shift work or requirement for a regular change in sleep schedule by at least six hours
             within the previous month.

          5. Pregnant or breastfeeding

          6. History of drug addiction, alcoholism, or drug abuse

          7. Currently using a benzodiazepine or SSRI or more than 2 days of use within the 28 days
             preceding randomization.

          8. A positive urine drug screen for compounds that would interfere with the assessment of
             a hypnotic.

          9. Use of prescription and non-prescription sedative drugs;

         10. Prior failure to respond to escitalopram therapy for anxiety

         11. The presence of any untreated or uncompensated clinically significant renal,
             endocrine, gastrointestinal, hepatic, respiratory, cardiovascular, other neurologic,
             hematologic, oncologic, immunologic, cerebrovascular disease or malignancy.

         12. History of sleep apnea

         13. History of myasthenia gravis

         14. Known hypersensitivity and/or allergy to or previous adverse experience with zolpidem
             or escitalopram or any of their excipients

         15. Subject is currently participating in another clinical trial (or within 28 days of
             screening).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis Diener</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2006</study_first_posted>
  <last_update_submitted>October 11, 2007</last_update_submitted>
  <last_update_submitted_qc>October 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

